Lexicon Pharmaceuticals financials
$1.88−1.05%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $49.6M | $31.0M | $1.1M | $0.00 | $0.00 | $23.4M | $321.6M | $62.9M | $91.5M | $79.1M |
| Gross profit | $49.4M | $30.4M | $1.0M | $0.00 | $0.00 | $21.5M | $318.3M | $60.4M | $89.6M | $79.1M |
| Gross margin | 99.4% | 98.0% | 92.3% | — | — | 91.8% | 99.0% | 96.0% | 97.9% | 100.0% |
| Operating income | -$49.1M | -$197.2M | -$171.8M | -$103.7M | -$88.2M | -$180.9M | $140.9M | -$103.6M | -$128.7M | -$128.0M |
| Net income | -$50.3M | -$200.4M | -$177.1M | -$101.9M | -$87.8M | -$58.6M | $130.1M | -$120.5M | -$123.0M | -$131.4M |
| Net margin | −101.4% | −646.4% | −15956.7% | — | — | −249.9% | 40.5% | −191.8% | −134.4% | −166.2% |
| Diluted EPS | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.16 | $-1.14 | $-1.17 | $-1.27 |
| EBITDA | -$48.4M | -$196.7M | -$171.3M | -$103.3M | -$87.9M | -$176.4M | $173.2M | -$100.0M | -$125.3M | -$126.0M |
| Operating cash flow | -$67.9M | -$178.8M | -$161.9M | -$88.9M | -$87.0M | -$143.0M | $113.8M | -$148.6M | -$185.4M | -$175.6M |
| Free cash flow | -$67.9M | -$179.8M | -$162.4M | -$90.2M | -$88.2M | -$143.1M | $113.7M | -$148.7M | -$185.6M | -$175.9M |
| Diluted shares | 363.1M | 320.0M | 221.1M | 165.7M | 145.7M | 110.8M | 116.7M | 105.8M | 105.2M | 103.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $34.3M | $66.7M | $22.5M | $46.3M | $64.1M | $126.3M |
| Short-term investments | $61.9M | $171.3M | $147.6M | $92.0M | $22.7M | $26.0M |
| Total debt | $54.0M | $100.3M | $99.5M | $48.6M | $0.00 | $11.6M |
| Total assets | $185.0M | $298.4M | $229.4M | $194.3M | $136.9M | $203.8M |
| Total liabilities | $77.4M | $152.5M | $136.3M | $77.2M | $23.3M | $47.4M |
| Shareholders' equity | $107.5M | $145.9M | $93.1M | $117.1M | $113.6M | $156.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology